The class action complaint, filed by law firm Glancy Prongay Wolke & Rotter LLP, centers on statements made between May 8, 2025, and March 30, 2026. According to the filing, Phreesia executives allegedly maintained a facade of long-term growth confidence while simultaneously downplaying risks associated with the firm's Network Solutions segment. The suit contends these projections were misleading, particularly regarding the durability of pharmaceutical marketing commitments intended to anchor the company's 2027 revenue targets.

Shareholders who purchased Phreesia stock during the specified window and suffered losses may contact attorney Charles Linehan in Los Angeles for counsel. Participation as a lead plaintiff is voluntary, and investors who choose not to act remain part of the class as absent members unless they opt out or retain independent legal representation.